安徽华人健康医药股份有限公司 第一章 总则 第二章 信息披露暂缓与豁免的适用情形 第一条 为规范安徽华人健康医药股份有限公司（以下简称"公司"）信息披 露暂缓与豁免行为，确保公司依法合规履行信息披露义务，保护投资 者的合法权益，根据《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司信息披露暂缓与豁免管理规定》《深圳证券交 易所创业板股票上市规则》（以下简称"《上市规则》"）等相关法 律法规，并结合《公司章程》及公司《信息披露管理制度》等有关规 定，制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告，在定期报告、 临时报告中豁免披露按照中国证券监督管理委员会（以下简称"中国 证监会"）及深圳证券交易所（以下简称"深交所"）规定或者要求披 露的内容，适用本制度。 第三条 公司应当审慎确定信息披露暂缓、豁免事项，并采取有效措施防止暂 缓或者豁免披露的信息泄露。 第四条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地披 露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者， 不得实施内幕交易、操纵市场等违法行为。 第十四条 公司和其他信息披露义务人应当在年度报告、半 ...

Core Points - The implementation details of the cumulative voting system aim to enhance the corporate governance structure of Anhui Huaren Health Pharmaceutical Co., Ltd. and protect the interests of minority shareholders [3] - The cumulative voting system allows shareholders to allocate their voting rights across multiple candidates when electing two or more directors, providing flexibility in voting [3][5] - The election process for directors must comply with the company's articles of association and relevant laws, ensuring a structured and transparent nomination and voting process [3][4] Section Summaries General Provisions - The cumulative voting system is established to improve corporate governance and protect minority shareholders' interests, in accordance with relevant laws and regulations [3] - The system allows shareholders to have voting rights equal to the number of shares they hold multiplied by the number of directors to be elected [3] Election and Voting of Directors - The board must inform shareholders about the cumulative voting method before the election, and appropriate ballots must be prepared [2][3] - The election of independent and non-independent directors is conducted separately, with specific voting rights allocated for each category [5] - Shareholders can concentrate or distribute their votes among candidates, but exceeding the allowed number of votes will render the ballot invalid [5] Nomination of Director Candidates - Candidates for the board must be nominated by shareholders holding at least 1% of the company's shares or by the board itself [3] - Nominators must obtain consent from candidates and ensure they meet the qualifications for directorship [3][4] Election Results and Procedures - The number of elected directors must meet the requirements set forth in the company's articles of association, with a majority of votes needed for election [4] - If the number of elected directors is insufficient, additional rounds of voting will be conducted until the required number is met [4]

Core Viewpoint - The document outlines the procedures and requirements for selecting and changing accounting firms for Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the importance of maintaining independence and quality in the auditing process [1][2][3]. Group 1: General Principles - The audit fees for the accounting firm are determined by the shareholders' meeting [1] - The controlling shareholders and actual controllers are prohibited from designating accounting firms or interfering with the audit committee's independent duties [1] - The selection of accounting firms must comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][2] Group 2: Requirements for Accounting Firms - Selected accounting firms must possess independent qualifications and meet the requirements set by the China Securities Regulatory Commission [1][2] - Firms must have a fixed workplace, sound organizational structure, and robust internal management systems [1] - The auditing team must include registered accountants who have not faced criminal or administrative penalties related to their professional conduct in the last three years [1][2] Group 3: Selection Procedures - The audit committee, independent directors, or a majority of the board can propose the hiring of an accounting firm [2][3] - The selection process must be competitive, utilizing methods such as competitive negotiation, public bidding, or invitation to tender [2][3] - The company must publicly disclose the selection documents, including evaluation criteria and scoring standards [2][3] Group 4: Evaluation and Reporting - The audit committee is responsible for evaluating the performance of the accounting firm annually and reporting to the board [2][3] - Evaluation criteria must include audit fees, qualifications, quality management, and risk management capabilities [4][5] - Significant changes in audit fees (over 20%) must be disclosed, including reasons for the change [6] Group 5: Change of Accounting Firms - The company must change accounting firms under specific circumstances, such as quality issues or failure to meet obligations [8][9] - The audit committee must communicate with both the outgoing and incoming firms to assess quality and integrity [9][10] - The reasons for changing firms must be disclosed, along with communication details with the previous firm [11][12]

安徽华人健康医药股份有限公司 防范控股股东及关联方资金占用管理制度 第一章 总则 第一条 为进一步完善安徽华人健康医药股份有限公司（以下简称"公司"）的法 人治理结构，加强资金管理， 应当严格防止公司 资金被占用。 其他方式向其提供资金； 防止和杜绝控股股东及关联方占用公司资金 行为的发生， 保护公司、股东和其他利益相关方的合法权益。根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司治理准则》、《深 圳证券交易所创业板股票上市规则》（以下简称"《股票上市规则》" ）、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》（以下简称"《规范运作指引》"）等法律、法规、规范 性文件和《安徽华人健康医药股份有限公司章程》（以下简称"公司章 程"）等规定，结合公司实际情况，特制定本制度。 经营性资金占用，是指公司控股股东及关联方通过采购、销售等生产经 营环节的关联交易所产生的资金占用；非经营性资金占用，是指公司为 控股股东及关联方垫付工资、福利、保险、广告等费用和其它支出，代 控股股东及关联方偿还债务而支付资金，有偿或无偿、直接 ...

General Principles - The company establishes an external guarantee management system to ensure the protection of investors' rights and the safety of company assets [1][2] - External guarantees refer to the company providing guarantees for the debts of others, excluding guarantees for its own debts [1][2] Approval Process for External Guarantees - External guarantee matters must be approved by the company's board of directors or shareholders' meeting [4][5] - The board must investigate the financial and operational status of the guaranteed party before making a decision [5][6] - Certain external guarantees require submission to the shareholders' meeting for approval, including guarantees exceeding 10% of the company's latest audited net assets [6][7] Management of Guarantee Contracts - Approved guarantee projects must be formalized in written contracts that comply with relevant laws and regulations [14][15] - The company must manage guarantee contracts and related documents diligently, ensuring their completeness and accuracy [15][16] - The finance department is responsible for monitoring the financial status of the guaranteed party and reporting to the board [16][17] Disclosure Obligations - The company must disclose information about external guarantees in a timely manner, including details about the guarantee situation and any overdue guarantees [21][22] - Confidentiality measures must be taken to limit the number of individuals aware of guarantee information before it is publicly disclosed [22][23] Accountability Mechanism - The board of directors is responsible for interpreting the guarantee management system [29] - Individuals who sign guarantee contracts without proper authorization may be held liable for any resulting losses to the company [24][25] - Directors who violate laws or regulations in the guarantee decision-making process may face joint liability for losses incurred [26][27]

Core Viewpoint - The core purpose of market value management is to align the company's market value with its intrinsic value by focusing on core business, enhancing operational efficiency, and improving core competitiveness [1][3]. Group 1: Objectives and Principles of Market Value Management - The primary objective of market value management is to enhance the company's value creation capability through effective information disclosure and investor relations management [1]. - The basic principles of market value management include compliance, systematic approach, scientific methods, normalization, and proactivity [4][2]. Group 2: Organizational Structure and Responsibilities - The board of directors leads the market value management efforts, with the chairman as the primary responsible person and the board secretary overseeing specific tasks [6]. - The board is responsible for establishing an internal control system for market value management, focusing on improving company quality and considering investor interests in major decisions [6]. Group 3: Main Methods of Market Value Management - Key methods for promoting the company's investment value include mergers and acquisitions, equity incentives, cash dividends, investor relations management, information disclosure, and share buybacks [7][6]. - The company should focus on its core business and improve operational efficiency while utilizing various methods to reflect the company's quality in its investment value [7][6]. Group 4: Monitoring and Early Warning Mechanism - The securities department is responsible for monitoring market value indicators and setting reasonable warning thresholds to analyze and report any significant changes [7]. - In the event of a significant or continuous decline in stock price, the company should take timely measures to analyze the reasons, communicate with investors, and potentially implement share buybacks or cash dividends [7].

Core Points - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., was established to protect the rights and interests of shareholders, employees, and creditors, and to regulate its organization and behavior according to relevant laws [3][4] - The company was registered with a capital of RMB 400.01 million and is a permanent corporation [4][5] - The company issued 60.01 million shares to the public and was listed on the Shenzhen Stock Exchange on March 1, 2023 [3][4] Chapter Summaries General Provisions - The company is established in accordance with the Company Law and other relevant regulations [3] - The legal representative of the company is the chairman, who is responsible for civil activities conducted in the company's name [4][5] - The company operates under the principle of "quality first, integrity-based" [4][5] Business Objectives and Scope - The registered name of the company is Anhui Huaren Health Pharmaceutical Co., Ltd., with its address in Hefei City [4] - The business scope includes drug wholesale, food sales, medical device sales, and various consulting services [4][5] Shares - The company has issued a total of 40.01 million shares, all of which are ordinary shares [6] - The company can provide financial assistance for others to acquire its shares, with a limit of 10% of the total issued capital [6][7] Shareholder and Shareholder Meeting - Shareholders have rights to dividends, attend meetings, and supervise the company's operations [16][19] - The company must hold an annual general meeting within six months after the end of the previous fiscal year [26][27] - Shareholders holding more than 10% of shares can request a temporary meeting [29][30] Voting and Resolutions - Resolutions can be ordinary or special, requiring a majority or two-thirds majority of the voting rights, respectively [79] - The company must ensure that the meeting records are accurate and preserved for at least ten years [41]

General Overview - The document outlines the working rules for the Secretary of the Board of Anhui Huaren Health Pharmaceutical Co., Ltd, aiming to improve corporate governance and clarify the rights, obligations, and responsibilities of the board secretary [1][2]. Responsibilities of the Board Secretary - The board secretary is responsible for handling information disclosure, managing investor relations, and coordinating communication between the company and various stakeholders [6][7]. - The board secretary must ensure the timely, accurate, complete, and lawful disclosure of information [2][3]. - The board secretary is tasked with organizing board and shareholder meetings, maintaining meeting records, and ensuring compliance with relevant laws and regulations [6][7]. Qualifications for the Board Secretary - The board secretary must possess necessary financial, management, and legal knowledge, and must adhere to high ethical standards [4][5]. - Individuals with certain disqualifying conditions, such as recent administrative penalties or market bans, are prohibited from serving as board secretary [4][5]. Appointment and Dismissal Procedures - The board secretary is appointed by the board for a term of three years, which aligns with the board's term [4][5]. - Dismissal of the board secretary requires sufficient justification, and the company must report the reasons for dismissal to the Shenzhen Stock Exchange [4][5]. Additional Provisions - The company must provide necessary conditions for the board secretary to perform their duties effectively [6][7]. - In the event of a vacancy, the board must appoint an interim secretary and complete the appointment of a new secretary within a specified timeframe [7][8].

安徽华人健康医药股份有限公司 内幕信息知情人登记管理制度 第一章 总则 董事会秘书具体负责公司内幕信息的日常管理工作，证券部是公司信息 披露管理、投资者关系管理、内幕信息登记备案的日常办事机构。 公司审计委员会对内幕信息知情人登记管理制度实施情况进行监督。 第二章 内幕信息及内幕信息知情人的范围 第六条 本制度所指内幕信息是指根据《证券法》相关规定，涉及公司的经营、 财务或者对公司股票、证券及其衍生品种交易价格有重大影响的尚未公 开的信息。包括但不限于： （一）公司的经营方针和经营范围的重大变化； （二）公司的重大投资行为，公司在一年内购买、出售重大资产超过公 司资产总额百分之三十，或者公司营业用主要资产的抵押、质押、出售 或者报废一次超过该资产的百分之三十； （三）公司订立重要合同、提供重大担保或者从事关联交易，可能对公 司的资产、负债、权益和经营成果产生重要影响； （四）公司发生重大债务和未能清偿到期债务的违约情况； （五）公司发生重大亏损或者重大损失； （六）公司生产经营的外部条件发生的重大变化； （七）公司的董事、或者总裁发生变动，董事长或者总裁无法履行职责； （八）持有公司百分之五以上股份的股东或者 ...

安徽华人健康医药股份有限公司 第六条 投资者关系工作的目的是： 第七条 投资者关系工作的基本原则是： 投资者关系管理制度 第一章 总则 1 第一条 为进一步完善安徽华人健康医药股份有限公司（以下简称"公司"）治 理结构，规范公司投资者关系工作，加强公司与投资者和潜在投资者（以 下统称"投资者"）之间的沟通，加深投资者对公司的了解和认同，促 进公司和投资者之间长期、稳定的良好关系，提升公司的诚信度、核心 竞争能力和持续发展能力，实现公司价值最大化和股东利益最大化，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司投资者关 系管理工作指引》《深圳证券交易所创业板股票上市规则》（以下简称 "《股票上市规则》"）、《深圳证券交易所上市公司自律监管指引第2 号——创业板上市公司规范运作》等法律、法规、规范性文件及公司章 程的规定，结合公司实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动交流 和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资 者对上市公司的了解和认同，以提升公司治理水平和企业整体 ...